Combination Therapy May Improve Survival in Nasopharyngeal Carcinoma

Share this content:
Induction chemotherapy with concurrent chemoradiotherapy may improve survival of patients with nasopharyngeal cancer.
Induction chemotherapy with concurrent chemoradiotherapy may improve survival of patients with nasopharyngeal cancer.

Induction chemotherapy with concurrent chemoradiotherapy may improve survival of patients with nasopharyngeal cancer, according to a study published in The Lancet Oncology.1

Distant metastases are the most common reason for a patient's failing treatment. For this phase 3 study, researchers tested whether induction chemotherapy, consisting of docetaxel, cisplatin, and fluorouracil, plus concurrent chemoradiotherapy is more efficacious than concurrent chemoradiotherapy alone.

Of 480 enrolled patients, 241 were randomized to induction plus concurrent therapy, and 239 were randomized to concurrent therapy only. Karnofsky performance status, age, and disease stage were balanced between the 2 groups.

After 3 years, 26 patients in the combination group and 43 patients in the concurrent therapy group had died. Failure-free survival and distant failure-free survival were 80% and 90% in the combination group, respectively, and 72% and 83% in the concurrent therapy group, respectively.

Response to treatment was, however, nearly the same between the 2 groups. There were 42 grade 4 adverse events in the combination group; there were only 3 in the concurrent therapy group.

RELATED: ERCC1 Genotype Can Identify Good Prognosis in Nasopharyngeal Cancer

The authors conclude that induction and concurrent therapy may improve survival over concurrent chemoradiotherapy only, though further follow-ups must confirm this finding. The toxicity of the combination therapy suggests it should not be used for elderly patients.

Five-year follow-up findings of overall survival and late toxic effects will be reported.

Reference

  1. Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016 Sep 26. doi: 10.1016/S1470-2045(16)30410-7 [Epub ahead of print] 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs